Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Kris L L, Movig"'
Autor:
Sem M. M. Hermans, Jorm M. Nellensteijn, Rob Knoef, Henk van Santbrink, Ruud Droeghaag, Jasper Most, Mattheus K. Reinders, Daisy M. N. Hoofwijk, Jan W. Potters, Kris L. L. Movig, Inez Curfs, Wouter L. W. van Hemert
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract During the first postoperative days following minimally invasive sacroiliac joint fusion (MISJF), patients often report serious pain, which contributes to high utilization of painkillers and prevention of early mobilization. This prospective
Externí odkaz:
https://doaj.org/article/5984a2c6b17141f990270855a07d0b99
Autor:
Nicol G. M. Oonk, Lucille D. A. Dorresteijn, Eline te Braake, Kris L. L. Movig, Job van der Palen, Henk-Willem Nijmeijer, Mirjam E. van Kesteren, Christina Bode
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 15 (2024)
Background: Executing structured medication reviews (SMRs) in primary care to optimize drug treatment is considered standard care of community pharmacists in the Netherlands. Patients with Parkinson’s disease (PD) often face complex drug regimens f
Externí odkaz:
https://doaj.org/article/6a3effec03ef463f94bb250afaef2f6b
Autor:
Rosanne W. Meijboom, Helga Gardarsdottir, Matthijs L. Becker, Kris L. L. Movig, Johan Kuijvenhoven, Toine C. G. Egberts, Thijs J. Giezen
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: Many patients with inflammatory bowel disease (IBD) have transitioned from an infliximab originator to a biosimilar. However, some patients retransition to the originator (i.e. stop biosimilar and reinitiate the originator). Whether this
Externí odkaz:
https://doaj.org/article/77aacd70d06b45e8b69c4b191557d5ba
Autor:
Esther T. Sportel, Martijn J. Oude Wolcherink, Job van der Palen, Anke Lenferink, Boony J. Thio, Kris L. L. Movig, Marjolein G. J. Brusse-Keizer
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-11 (2020)
Abstract Background Many asthmatic children suffer from uncontrolled asthma with frequent exacerbations, despite an optimal treatment plan using inhalation medication. Studies have shown that therapy adherence and inhalation technique are often subop
Externí odkaz:
https://doaj.org/article/81499a84a8a84cd6a65c0c0f6e0b6823
Publikováno v:
Clinical Case Reports, Vol 9, Iss 11, Pp n/a-n/a (2021)
Abstract Background Acetaminophen hepatotoxicity is thought to be primarily caused by formation of the specific reactive metabolite N‐acetyl‐para‐benzo‐quinone imine (NAPQI). Malnourished individuals are at increased risk of acetaminophen‐r
Externí odkaz:
https://doaj.org/article/f3eaae8c5ba54ab6988fb92bf2126695
Autor:
Rosanne W. Meijboom, Helga Gardarsdottir, Matthijs L. Becker, Mark C. H. de Groot, Kris L. L. Movig, Johan Kuijvenhoven, Toine C. G. Egberts, Hubert G. M. Leufkens, Thijs J. Giezen
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 4, Pp n/a-n/a (2021)
Abstract The aim of this study was to assess switching patterns and determinants for switching in patients initiating TNFα inhibitor (TNFα‐i) treatment. Patients were included who started TNFα‐i treatment between July 1, 2012 and December 31,
Externí odkaz:
https://doaj.org/article/2c96570847574c73a0f95842dfcf6377
Autor:
Willemien J Kruik-Kollöffel, Job van der Palen, Carine J M Doggen, Marissa C van Maaren, H Joost Kruik, Edith M Heintjes, Kris L L Movig, Gerard C M Linssen
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0244231 (2020)
BackgroundThis study assessed the association between heart failure (HF) medication (angiotensin-converting-enzyme inhibitors (ACEI)/angiotensin-receptor blockers (ARB), beta-blockers (BB), mineralocorticoid-receptor antagonists (MRA) and diuretics)
Externí odkaz:
https://doaj.org/article/83754b373c934081bd5365b6842c3062
Autor:
Willemien J. Kruik-Kollöffel, Enriqueta Vallejo-Yagüe, Kris L. L. Movig, Gerard C. M. Linssen, Edith M. Heintjes, Job van der Palen
Publikováno v:
International Journal of Clinical Pharmacy, 44(3), 762-768. Springer
Background: Among heart failure (HF) patients, hospital readmissions are a major concern. The medication taken by a patient may provide information on comorbidities and conditions and may be used as an indicator to identify populations at an increase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a614211e18a84ac3f0c587151af5f5d
https://doi.org/10.1007/s11096-022-01418-3
https://doi.org/10.1007/s11096-022-01418-3
Autor:
Mirjam E. van Kesteren, Kris L. L. Movig, Nicol G.M. Oonk, Henk Willem Nijmeijer, Lucille D.A. Dorresteijn, Job van der Palen
Publikováno v:
Clinical Drug Investigation, 41, 809-816. Adis International Ltd
Background and Objectives: Quality of life (QoL) in Parkinson’s disease (PD) depends on multiple factors. Due to PD treatment and accompanying, age-related or independent comorbidities, pill burden is often high. The relation of QoL and pharmacothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df156ea69b2e2eddbfc0b1a99041933a
http://www.scopus.com/inward/record.url?scp=85112172827&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85112172827&partnerID=8YFLogxK
Autor:
Marieke G M Weernink, Janine A van Til, Jeroen P P van Vugt, Kris L L Movig, Catharina G M Groothuis-Oudshoorn, Maarten J IJzerman
Publikováno v:
PLoS ONE, Vol 11, Iss 8, p e0160771 (2016)
INTRODUCTION:Little is known about how patients weigh benefits and harms of available treatments for Parkinson's Disease (oral medication, deep brain stimulation, infusion therapy). In this study we have (1) elicited patient preferences for benefits,
Externí odkaz:
https://doaj.org/article/fa64676ce73f4e498eac4e21d82df046